Regulatory T cell levels in migraine: A systematic review and meta-analysis
Abstract
BACKGROUND: Although recent research suggests that regulatory T (Treg) cells may be involved in migraine pathophysiology, no review has provided a comprehensive assessment of their levels in this condition. This systematic review and meta-analysis aims to assess Treg levels in migraine patients. METHODS: We systematically searched PubMed, Embase and Cochrane on July 5, 2024 (updated on March 19, 2026), and included all original studies providing data on Treg levels in migraine. RESULTS: Among 1,162 studies identified, five were included in the narrative review and four in the meta-analysis. Data were pooled using a random-effects model. Standardized mean differences (SMD) were calculated to compare peripheral whole blood Treg levels between migraine and control groups. Our narrative review showed decreased Treg levels in three of five studies comparing migraine patients and controls, and in two of three studies on interictal episodic migraine patients and controls. Our meta-analysis of few but carefully selected data suggested a significant decrease in Treg cell levels in migraine (SMD - 4.21 [-7.76; -0.66], p = 0.02, I²=98.3%). CONCLUSIONS: Our findings suggest Treg levels are decreased in migraine and of potential interest in understanding migraine pathophysiology. However, the limited data available warrant further investigations to shed light on their relevance and therapeutic potential in this condition. TRIAL REGISTRATION: PROSPERO CRD42023490445. CLINICAL TRIAL NUMBER: Not applicable.
Related
- Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface
- Molecular Mechanisms, Evidence Levels, and Translational Prospects of Natural Products in Non-Small Cell Lung Cancer: A Critical Narrative Review
- Effects of exercise interventions on leptin and ghrelin levels in middle-aged and older adults with overweight or obesity: a systematic review and meta-analysis
- Evaluation of the Translational Readiness of Pluripotent Stem Cell-Derived Vascular Cell Therapy for Limb Ischemia: A Systematic Review and Meta-analysis
- Limitations and Strengths of the SH ‐ SY5Y Neuroblastoma Cell Line as a Model of β‐Amyloid Neurotoxicity: Lessons From a Systematic Review and Meta‐Analysis
BibTeX
@article{stuchfielddenby2026regulatory,
title = {{Regulatory T cell levels in migraine: A systematic review and meta-analysis}},
author = {Emily Stuchfield-Denby and Samuel Adelou and Xavier Moisset and Radhouane Dallel},
journal = {Journal of Headache and Pain},
year = {2026},
month = jul,
doi = {10.1186/s10194-026-02443-7},
url = {https://hal.science/hal-05794362v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Regulatory T cell levels in migraine: A systematic review and meta-analysis
AU - Emily Stuchfield-Denby
AU - Samuel Adelou
AU - Xavier Moisset
AU - Radhouane Dallel
PY - 2026
DA - 2026/07/16
JO - Journal of Headache and Pain
DO - 10.1186/s10194-026-02443-7
UR - https://hal.science/hal-05794362v1
AB - BACKGROUND: Although recent research suggests that regulatory T (Treg) cells may be involved in migraine pathophysiology, no review has provided a comprehensive assessment of their levels in this condition. This systematic review and meta-analysis aims to assess Treg levels in migraine patients. METHODS: We systematically searched PubMed, Embase and Cochrane on July 5, 2024 (updated on March 19, 2026), and included all original studies providing data on Treg levels in migraine. RESULTS: Among 1,162 studies identified, five were included in the narrative review and four in the meta-analysis. Data were pooled using a random-effects model. Standardized mean differences (SMD) were calculated to compare peripheral whole blood Treg levels between migraine and control groups. Our narrative review showed decreased Treg levels in three of five studies comparing migraine patients and controls, and in two of three studies on interictal episodic migraine patients and controls. Our meta-analysis of few but carefully selected data suggested a significant decrease in Treg cell levels in migraine (SMD - 4.21 [-7.76; -0.66], p = 0.02, I²=98.3%). CONCLUSIONS: Our findings suggest Treg levels are decreased in migraine and of potential interest in understanding migraine pathophysiology. However, the limited data available warrant further investigations to shed light on their relevance and therapeutic potential in this condition. TRIAL REGISTRATION: PROSPERO CRD42023490445. CLINICAL TRIAL NUMBER: Not applicable.
SN - 1129-2369
SN - 1129-2377
ER -